PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.58%
Negative EBIT growth while AGEN is at 41.92%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.34%
Negative operating income growth while AGEN is at 32.62%. Joel Greenblatt would press for urgent turnaround measures.
-20.40%
Negative net income growth while AGEN stands at 34.53%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-19.61%
Negative EPS growth while AGEN is at 38.80%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-20.61%
Negative diluted EPS growth while AGEN is at 38.80%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.76%
Share reduction more than 1.5x AGEN's 6.97%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.74%
Negative OCF growth while AGEN is at 7.97%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-26.42%
Negative FCF growth while AGEN is at 25.42%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91846.40%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-21838.35%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
2.60%
3Y OCF/share CAGR under 50% of AGEN's 20.80%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-1109485.80%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20425.82%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
78.21%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
41985.76%
10Y equity/share CAGR above 1.5x AGEN's 157.92%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
3459.24%
5Y equity/share CAGR above 1.5x AGEN's 362.40%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
143.15%
Positive short-term equity growth while AGEN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Negative asset growth while AGEN invests at 29.48%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-29.04%
We have a declining book value while AGEN shows 121.28%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth drastically higher vs. AGEN's 25.62%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
12.93%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.